Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub ...

YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and strategic direction of this open-source ecosystem ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care ...

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Stealing the Show. Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold ...

Tempus AI’s TEM strategic focus for 2026 centers on expanding its AI-driven precision medicine platform by scaling the ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. “Staying current with rapidly evolving clinical guidelines—especially regarding biomarker ...